Daiichi Sankyo US, Merck collaborate to develop and commercialize MK-6070, an investigational delta-like ligand 3 targeting T-cell engager. https://lnkd.in/eBdF9QKu
The Cancer Letter
Newspaper Publishing
Washington, District of Columbia 2,148 followers
The leading independent source for information on the issues that shape oncology since 1973.
About us
The Cancer Letter, an independent weekly news publication, has been the leading source for information on the issues that shape oncology since 1973. The Cancer Letter provides authoritative, award-winning coverage of the development of cancer therapies, drug regulation, legislation, cancer research funding, health care finance, and public health. Our coverage focuses on the National Cancer Institute, National Institutes of Health, Food & Drug Administration, U.S. Congress, cancer centers, and the pharmaceutical industry. The Cancer Letter’s readers include key opinion leaders at academic institutions, community oncology practices, government agencies, professional associations, health IT and pharmaceutical companies, Wall Street, and advocacy organizations. Based in Washington, D.C., The Cancer Letter has earned acclaim for its investigative work. It has been profiled and cited in outlets including The New York Times, The Washington Post, 60 Minutes, CNN, NPR, Science, and Nature. Coverage by The Cancer Letter has triggered multiple investigations by Congressional committees, the Institute of Medicine, the Federal Trade Commission, the Securities and Exchange Commission, and the Department of Justice, and contributed to federal action by the FDA, the Centers for Disease Control and Prevention, the Federal Bureau of Investigation, and Government Accountability Office.
- Website
-
https://cancerletter.com
External link for The Cancer Letter
- Industry
- Newspaper Publishing
- Company size
- 2-10 employees
- Headquarters
- Washington, District of Columbia
- Type
- Privately Held
- Founded
- 1973
- Specialties
- Oncology, Journalism, and Cancer
Locations
-
Primary
Get directions
The Cancer Letter Inc.
Washington, District of Columbia 20016, US
Employees at The Cancer Letter
Updates
-
Updated ArteraAI Prostate Test informs active surveillance decisions for lower-risk prostate cancer. https://lnkd.in/gQBnmU-R
-
-
Steven Mitchell Cohen named director of robotic pancreas surgery at Northwell Health. https://lnkd.in/gYswqFnv
-
-
Wafik El-Deiry carted a bunch of books around the Mediterranean. Here are his reviews. Book review by Wafik El-Deiry. https://lnkd.in/ghUmfpSX
-
-
Distinct pattern in protein production can predict severe side effects from skin cancer treatment (led by researchers at NYU Langone Health). https://lnkd.in/g9MhEZ-h
-
-
Cheng-Chia Wu joins Fralin Biomedical Research Institute at VTC. https://lnkd.in/efFcbD27
-
-
FDA grants de novo authorization for kitted, pan-solid tumor liquid biopsy test (Labcorp). https://lnkd.in/e85Feu_H
-
-
Senate Appropriations Committee slates $1.77B increase for The National Institutes of Health, $270M for National Cancer Institute (NCI) in FY25. https://lnkd.in/eBHYEK_D
-
-
Why Bernie Fisher deserves a biography (and why I am writing it). Guest editorial by Stacy Wentworth. https://lnkd.in/e62UtPV9
-
-
Five-year study (Moffitt Cancer Center) identifies long-term effects of axi-cel CAR T treatment. https://lnkd.in/e5rRgqHY
-